InMed Pharmaceuticals

📍 Vancouver, Canada👥 16 employees💰 Last funded Nov 2015
Biotechnology Research🌐 inmedpharma.com
Website LinkedIn
InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com. Nasdaq: INM
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in InMed Pharmaceuticals?
InMed Pharmaceuticals has 1 investor on record on gritt.io.
When did InMed Pharmaceuticals last raise funding?
The most recent investment in InMed Pharmaceuticals recorded on gritt.io was in November 2015.
What industry is InMed Pharmaceuticals in?
InMed Pharmaceuticals operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is InMed Pharmaceuticals based?
InMed Pharmaceuticals is headquartered in Vancouver, Canada.